These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39417187)

  • 1. Attenuation of aggressive tumor progression of anaplastic thyroid cancer by p53.
    Hwang E; Kruhlak M; Wong N; Chari R; Kimura T; Cheng SY
    Am J Cancer Res; 2024; 14(9):4429-4444. PubMed ID: 39417187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
    Cuddihy AR; Jalali F; Coackley C; Bristow RG
    Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild-Type P53 Induces Sodium/Iodide Symporter Expression Allowing Radioiodide Therapy in Anaplastic Thyroid Cancer.
    Liu L; Li D; Chen Z; Yang J; Ma Y; Cai H; Shan C; Lv Z; Zhang X
    Cell Physiol Biochem; 2017; 43(3):905-914. PubMed ID: 28957796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
    Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
    Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
    [No Abstract]   [Full Text] [Related]  

  • 7. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.
    Liang Y; Besch-Williford C; Benakanakere I; Hyder SM
    Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.
    Weilbacher A; Gutekunst M; Oren M; Aulitzky WE; van der Kuip H
    Cell Death Dis; 2014 Jul; 5(7):e1318. PubMed ID: 25010984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
    Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
    Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
    Liang Y; Besch-Williford C; Hyder SM
    Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
    Zhang K; Yu M; Hao F; Dong A; Chen D
    Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways.
    Park CH; Han SE; Nam-Goong IS; Kim YI; Kim ES
    Endocrinol Metab (Seoul); 2018 Mar; 33(1):121-132. PubMed ID: 29589394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.
    Said R; Hong DS; Warneke CL; Lee JJ; Wheler JJ; Janku F; Naing A; Falchook GS; Fu S; Piha-Paul S; Tsimberidou AM; Kurzrock R
    Oncotarget; 2013 May; 4(5):705-14. PubMed ID: 23670029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
    Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
    Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein.
    Vinyals A; Peinado MA; Gonzalez-Garrigues M; Monzó M; Bonfil RD; Fabra A
    Gene Ther; 1999 Jan; 6(1):22-33. PubMed ID: 10341872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity.
    Zhu X; Zhao L; Doolittle WKL; Cheng SY
    Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36939877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells.
    Pilli T; Cantara S; Marzocchi C; Pacini F; Prabhakar BS; Castagna MG
    Endocrine; 2020 Jan; 67(1):117-123. PubMed ID: 31377969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage-Induced Carboxypeptidase A4 Promotes the Progression of Anaplastic Thyroid Cancer.
    Choi YS; Jeon MJ; Doolittle WKL; Song DE; Kim K; Kim WB; Kim WG
    Thyroid; 2024 Sep; 34(9):1150-1162. PubMed ID: 38666696
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.